A Study to Evaluate Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
Official Title
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa
Purpose
This study is being done to see how well remibrutinib works for people who have hidradenitis suppurativa
Could this study be right for you?
- Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas
- Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C
- Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke
- Subject must not be taking anticoagulant medication (ex. warfarin) or dual anti-platelet therapy (ex. acetylsalicylic acid + clopidogrel)